Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 13/20 | 0.42 |
| ▸ | KDM5A | P29375 | 8/20 | 0.42 |
| ▸ | KDM5C | P41229 | 6/20 | 0.42 |
| ▸ | KDM4A | O75164 | 3/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19741677 | 1.00 | KDM5B (0.42) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741649 | 0.91 | KDM5B (0.45) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741646 | 0.91 | KDM5B (0.45) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741736 | 0.84 | KDM5B (0.37) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741710 | 0.84 | KDM5B (0.37) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741738 | 0.83 | KDM5B (0.42) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741740 | 0.83 | KDM5B (0.42) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741627 | 0.81 | KDM5B (0.35) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741626 | 0.81 | KDM5B (0.35) | KDM5BKDM5AKDM5CKDM4AKDM6B | |
| SCHEMBL19741642 | 0.80 | KDM5B (0.41) | KDM5BKDM5AKDM5CKDM4AKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | claimed |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM3A, KDM1A | KDM5B 33/4885KDM5A 23/4885KDM5C 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.